– UK, London – Synthace, creators of the world’s first digital life science experiment platform, today announced the appointment of Dr. Donald Deieso as Chairman of its Board of Directors, succeeding Bob Wiederhold who served as Board Chair since 2018.
“I speak for the entire company when I say that we are delighted to welcome Don as the new chair of our board,” said CEO, Dr. Guy Levy-Yurista. “His experience and intimate knowledge of the life sciences industry are second to none. Not only does he have an astonishing career in the industry, but he also has a priceless understanding of the entire pharmaceutical value chain. In short: Don knows what drives the most value to life science organizations, and he knows how to realize that value as well. It’s his expertise that will make the difference in our ability to scale and meet the needs of this industry.”
“When I first heard about Synthace, I could immediately see the importance of their mission,” said Dr. Donald Deieso. “They are already serving many of the world’s top pharmaceutical companies and enabling their customers to do incredible science with their platform. This is why I’m so pleased to be joining this extraordinary company; their multidisciplinary leadership team is particularly impressive and it will be my privilege to contribute to their mission.”
Currently, Dr. Deieso is serving on the boards of WCG Clinical, and Inspire. He is also a member of the Novo Holdings Advisory Group.
About Synthace
Based in London in the UK and Boston in the U.S., Synthace is a cloud-based experiment platform that enables life science,e R&Dteamsm,s to do experiments that would otherwise be impossible. It helps scientists innovate faster by automating high throughput experiments, structuring complex datasets, and allowing them to use powerful methodologies—like Design of Experiments—all from within their browser.
The Synthace platform fundamentally transforms and improves the relationship between what a scientist can imagine and what they can do in their lab. This means that instead of spending hours working with pen, paper, and pipettes, they can spend that time focused on answering the questions that will solve humanity’s most pressing problems.
For more information: https://www.synthace.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
